

Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application.

1. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound consisting of the formula X₁-SEQ ID NO:1-X₂ wherein

X₁ is from zero to twelve amino acids, and

X₂ is from zero to twelve amino acids.

2. (Original) The composition of Claim 1, wherein

X₁ is from zero to six amino acids, and

X₂ is from zero to six amino acids

3. (Original) The composition of claim 1 wherein

X₁ is

(i) zero amino acids, or

(ii) the segment SEQ ID NO:2, or N-terminal truncation fragment thereof containing at least one amino acid, and

X₂ is

(i) zero amino acids, or

(ii) the segment SEQ ID NO:3, or C-terminal truncation fragment thereof containing at least one amino acid.

4. (Original) The composition of claim 1 wherein the compound has substantial amino acid sequence homology to the amino acid sequence SEQ ID NO:4.

5. (Original) The composition of claim 1 wherein the compound has the amino acid sequence SEQ ID NO:1.

6. (Original) The composition of claim 1 wherein the compound has the amino acid sequence SEQ ID NO:9.

7. (Original) The composition of claim 1 wherein the compound has the amino acid sequence SEQ ID NO:10.

8 Cancelled

9. Cancelled

10. Cancelled

11. Cancelled

12. Cancelled

13. Cancelled

14. Cancelled

In re: Patent application of Keith R. McCrae
Attorney Docket No.: 6056-260; 35926-147539
Serial No.:09/461,061

15. Cancelled

16. Cancelled

17. Cancelled

18. Cancelled

19. Cancelled

20. Cancelled

21. Cancelled

22. Cancelled

23. Cancelled

24. (Original) A method of inhibiting angiogenesis comprising administering to a mammal an effective amount of a composition according to claim 1.

25. Cancelled

26. Cancelled

27. Cancelled

In re: Patent application of Keith R. McCrae
Attorney Docket No.: 6056-260; 35926-147539
Serial No.:09/461,061

- 28. Cancelled
- 29. Cancelled
- 30. Cancelled
- 31. Cancelled
- 32. Cancelled
- 33. Cancelled
- 34. Cancelled
- 35. Cancelled
- 36. Cancelled
- 37. Cancelled
- 38. Cancelled
- 39. Cancelled
- 40. Cancelled
- 41. Cancelled

42. Cancelled

43. Cancelled

44. Cancelled

45. Cancelled

46. Cancelled

47. Cancelled

48. Cancelled

49. (Previously presented) A method of inhibiting angiogenesis comprising administering to a mammal effective amount of a composition according to claim 2.

50. (Previously presented) A method of inhibiting angiogenesis comprising administering to a mammal effective amount of a composition according to claim 3.

51. (Previously presented) A method of inhibiting angiogenesis comprising administering to a mammal effective amount of a composition according to claim 4.

52. (Previously presented) A method of inhibiting angiogenesis comprising administering to a mammal effective amount of a composition according to claim 5.

53. (Previously presented) A method of inhibiting angiogenesis comprising administering to a mammal effective amount of a composition according to claim 6.

54. (Previously presented) A method of inhibiting angiogenesis comprising administering to a mammal effective amount of a composition according to claim 7.

55. (Previously presented) A method for inhibiting angiogenesis comprising administering to a mammal an effective amount of a compound of the formula X_1 -SEQ ID NO:1- X_2 wherein

X_1 is from zero to twelve amino acids, and

X_2 is from zero to twelve amino acids.

56. (Previously presented) A method of inhibiting angiogenesis according to claim 1 wherein

X_1 is

(i) zero amino acids, or

(ii) the segment SEQ ID NO:2, or N-terminal truncation fragment thereof containing at least one amino acid, and

X_2 is

(i) zero amino acids, or

(ii) the segment SEQ ID NO:3, or C-terminal truncation fragment thereof containing at least one amino acid.